PPIDT00196
Drug Information
| Name | Elotuzumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB06317 |
| Type | biotech |
| Indication | Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution | Intravenous |
300 mg/1
|
| Injection, powder, for solution | Intravenous |
300 mg
|
| Injection, powder, for solution | Intravenous |
400 mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
300 MG
|
| Injection, powder, for solution | Intravenous; Parenteral |
400 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
2500000 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
400 mg/1
|
| Powder, for solution | Intravenous |
340 mg / vial
|
| Powder, for solution | Intravenous |
440 mg / vial
|